# Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases

> **NCT06401824** · PHASE2 · RECRUITING · sponsor: **Maastricht University Medical Center** · enrollment: 25 (estimated)

## Conditions studied

- NSCLC Stage IV
- Brain Metastases, Adult

## Interventions

- **DRUG:** Sacituzumab Govitecan-Hziy 180 MG plus bevacizumab

## Key facts

- **NCT ID:** NCT06401824
- **Lead sponsor:** Maastricht University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-24
- **Primary completion:** 2026-11-01
- **Final completion:** 2027-04-01
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2025-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06401824

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06401824, "Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06401824. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*